<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3111">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01830101</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-Patel-01</org_study_id>
    <nct_id>NCT01830101</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Re-Irradiation in Recurrent Glioblastoma</brief_title>
  <official_title>A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hope to improve overall median survival of patients with recurrent
      Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five
      treatments of re-irradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a stratified study for patients with recurrent intracranial glioblastoma or
      gliosarcoma previously treated with concurrent chemoradiation presenting radiographic
      progression or recurrence of tumour. Patients are stratified by extent of resection, time to
      re-irradiation and re-irradiation volume.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study will not be proceeding due to lack of funding from anticipated sources
  </why_stopped>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the overall median survival of the combination of continuous dose-intense temozolomide with or without re-irradiation in patients with recurrent glioblastoma.</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate time to radiographic progression or recurrence of tumour following treatment with continuous dose-intense temozolomide with or without re-irradiation.</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>TMZ plus concurrent re-irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMZ plus concurrent re-irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMZ alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMZ alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ plus concurrent re-irradiation</intervention_name>
    <arm_group_label>TMZ plus concurrent re-irradiation</arm_group_label>
    <arm_group_label>TMZ alone</arm_group_label>
    <other_name>Temedol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>low-dose temozolomide daily for one year</description>
    <arm_group_label>TMZ plus concurrent re-irradiation</arm_group_label>
    <arm_group_label>TMZ alone</arm_group_label>
    <other_name>Temedol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically-proven intracranial glioblastoma or gliosarcoma previously treated
             with concurrent chemoradiation

          -  radiographic evidence of tumour progression or recurrence

          -  18 years or older

          -  ECOG 0 - 2

          -  signed informed consent form

        Exclusion Criteria:

          -  tumour progression or recurrence within 3 months of initial concurrent chemoradiation

          -  6 or more cycles of TMZ administered following chemoradiation at initial diagnosis

          -  more than one prior course of salvage chemo for recurrent disease

          -  prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for greater or equal to 3 years

          -  prior head or neck RT except for T1 glottic cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent glioblastoma</keyword>
  <keyword>re-irradiation</keyword>
  <keyword>continuous low-dose temozolomide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
